Literature DB >> 1330634

3-position modification of myo-inositol 1,4,5-trisphosphate: consequences for intracellular Ca2+ mobilisation and enzyme recognition.

S T Safrany1, R A Wilcox, C Liu, B V Potter, S R Nahorski.   

Abstract

The ability of the novel D-myo-inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) analogues, L-chiro-inositol 2,3,5-trisphosphate (L-ch-Ins(2,3,5)P3) and D-3-deoxy-3-fluoro-myo-inositol 1,4,5-trisphosphate (3F-Ins(1,4,5)P3), to bind to the Ins(1,4,5)P3 receptor, mobilise intracellular Ca2+ stores and interact with metabolic enzymes has been investigated. L-ch-Ins(2,3,5)P3 and 3F-Ins(1,4,5)P3 were bound by the Ins(1,4,5)P3 receptor from bovine adrenal cortex with relatively high affinity (Ki values 60.4 and 8.0 nM respectively) but with lower affinity than Ins(1,4,5)P3 (KD = 5.9 nM). Both analogues were apparent full agonists at the Ca2+ mobilising receptor in SH-SY5Y cells, but were less potent than Ins(1,4,5)P3 (EC50 L-ch-Ins(2,3,5)P3 = 1.4 microM, 3F-Ins(1,4,5)P3 = 0.37 microM and Ins(1,4,5)P3 = 0.12 microM). L-ch-Ins(2,3,5)P3 and 3F-Ins(1,4,5)P3 were resistant to Ins(1,4,5)P3 3-kinase, and were potent inhibitors of the enzyme (Ki values 7.1 and 8.6 microM respectively). 3F-Ins(1,4,5)P3 was hydrolysed by Ins(1,4,5)P3 5-phosphatase at a similar rate to Ins(1,4,5)P3, but inhibited dephosphorylation of [3H]Ins(1,4,5)P3 with high potency (apparent Ki = 3.9 microM) L-ch-Ins(2,3,5)P3 was also recognised by the enzyme with high affinity (Ki = 7.7 microM) but was resistant to hydrolysis. These results suggest that the environment around C-3 is of major importance for recognition not only by Ins(1,4,5)P3 3-kinase but also by Ins(1,4,5)P3 5-phosphatase.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1330634     DOI: 10.1016/0922-4106(92)90071-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Ca2+ store dynamics determines the pattern of activation of the store-operated Ca2+ current I(CRAC) in response to InsP3 in rat basophilic leukaemia cells.

Authors:  M D Glitsch; A B Parekh
Journal:  J Physiol       Date:  2000-03-01       Impact factor: 5.182

Review 2.  The "Other" Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in myo-Inositol Chemistry).

Authors:  Mark P Thomas; Stephen J Mills; Barry V L Potter
Journal:  Angew Chem Int Ed Engl       Date:  2015-12-22       Impact factor: 15.336

3.  Facilitation of the responses to injections of inositol 1,4,5-trisphosphate analogs in Limulus ventral photoreceptors.

Authors:  I Levitan; R Payne; B V Potter; P Hillman
Journal:  Biophys J       Date:  1994-09       Impact factor: 4.033

4.  Selective recognition of inositol phosphates by subtypes of the inositol trisphosphate receptor.

Authors:  E P Nerou; A M Riley; B V Potter; C W Taylor
Journal:  Biochem J       Date:  2001-04-01       Impact factor: 3.857

Review 5.  Pharmacological modulation of intracellular Ca(2+) channels at the single-channel level.

Authors:  P Koulen; E C Thrower
Journal:  Mol Neurobiol       Date:  2001 Aug-Dec       Impact factor: 5.682

6.  Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.

Authors:  Xiangbing Meng; Pavla Brachova; Shujie Yang; Zhi Xiong; Yuping Zhang; Kristina W Thiel; Kimberly K Leslie
Journal:  PLoS One       Date:  2011-06-08       Impact factor: 3.240

7.  Biological Regulatory Network (BRN) Analysis and Molecular Docking Simulations to Probe the Modulation of IP3R Mediated Ca2+ Signaling in Cancer.

Authors:  Humaira Ismatullah; Ishrat Jabeen; Muhammad Tariq Saeed
Journal:  Genes (Basel)       Date:  2020-12-29       Impact factor: 4.096

8.  Both d- and l-Glucose Polyphosphates Mimic d-myo-Inositol 1,4,5-Trisphosphate: New Synthetic Agonists and Partial Agonists at the Ins(1,4,5)P3 Receptor.

Authors:  Megan L Shipton; Andrew M Riley; Ana M Rossi; Charles A Brearley; Colin W Taylor; Barry V L Potter
Journal:  J Med Chem       Date:  2020-05-06       Impact factor: 7.446

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.